Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma.

Abstract

BACKGROUND:

Malignant mesothelioma (MM) is a highly aggressive tumour with poor prognosis and limited response to therapy. New markers for the prediction of prognosis in MM and in pulmonary adenocarcinoma of the pleura are valuable. GATA-6 belongs to a six member zinc finger transcription factor family named after their recognition motif W-GATA-R.

AIM:

To clarify the distribution and possible function of GATA-6 transcription factor in MM and in pleural metastasis of lung adenocarcinomas.

METHODS:

63 pleural MM and 36 pleural metastatic pulmonary adenocarcinomas were studied for GATA-6 expression by immunohistochemistry using tissue microarrays. Expression of GATA-6 was examined in relation to thyroid transcription factor-1 expression, survival, proliferation and apoptosis.

RESULTS:

Nuclear immunoreactivity for GATA-6 was stronger and more frequent in MM than in metastatic pleural adenocarcinoma. Prognosis was better in patients with GATA-6 expression when compared to those with no GATA-6 expression (p = 0.002); in the subgroup analysis the difference was significant in epithelial and sarcomatous mesothelioma. GATA-6 was not associated with spontaneous proliferation or apoptosis of the tumour cells in situ.

CONCLUSION:

Results suggest that GATA-6 plays a role in pleural malignancies, predicting longer survival in subgroups of MM.

• Authors: P M Lindholm, Y Soini, M Myllärniemi, S Knuutila, M Heikinheimo, V L Kinnula, K Salmenkivi
• Journal: Journal of clinical pathology (J Clin Pathol) Vol. 62 Issue 4 Pg. 339-44 (Apr 2009) ISSN: 1472-4146 [Electronic] England
• PMID: 19060016 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers, Tumor
• GATA6 Transcription Factor
• Neoplasm Proteins

Topics

• Adenocarcinoma (metabolism, pathology, secondary, surgery)
• Apoptosis
• Biomarkers, Tumor (metabolism)
• Cell Proliferation
• GATA6 Transcription Factor (metabolism)
• Humans
• Immunoenzyme Techniques
• In Situ Nick-End Labeling (methods)
• Lung Neoplasms (metabolism, pathology, secondary, surgery)
• Mesothelioma (metabolism, pathology, surgery)
• Neoplasm Proteins (metabolism)
• Pleural Neoplasms (metabolism, pathology, surgery)
• Prognosis
• Survival Analysis
• Tumor Cells, Cultured